<ul>
<li>3 只准备实现显著增长的小型股</li>
</ul>
<p>Aura Biosciences NASDAQ: AURA 的高管在 H.C. Wainwright Connect 会议上概述了公司针对其主要候选药物 bel-sar 的战略，强调眼科肿瘤学是公司初始的开发重点，同时讨论了在非肌肉侵袭性膀胱癌方面的持续工作。</p>
<p>获取 <strong>Aura Biosciences</strong> 的提醒：</p>
<p>Aura 的首席财务官兼首席商务官 Tony Gibney 表示，公司管线 “以 bel-sar 为基础”，他将其描述为一种在广泛的实体肿瘤中具有潜在应用的新型化合物。Aura 选择眼科肿瘤学作为其专有开发的 “立足点”，从脉络膜黑色素瘤开始，并扩展到脉络膜转移和眼表癌。</p>
<p>Gibney 还强调了在非肌肉侵袭性膀胱癌中进行的 1b/2 期研究，预计初步三个月的数据将在年中左右公布。他表示，该项目正在评估免疫消融机会和新辅助治疗方法。</p>
<h2>bel-sar 在脉络膜黑色素瘤中的作用</h2>
<p>Aura 眼科肿瘤学副总裁兼治疗领域负责人 Anthony Daniels 表示，bel-sar 的开发旨在解决早期脉络膜黑色素瘤的治疗困境：医生通常监测肿瘤的生长以延迟放疗，因为目前的放射治疗可能导致严重的视力丧失。</p>
<p>Daniels 表示，眼后部的黑色素瘤患者最终面临转移性疾病的风险，最常见的是肝脏转移。他表示，目前的治疗模式可能治疗得太晚，并补充说，bel-sar 的靶向肿瘤治疗可能产生肿瘤特异性免疫记忆，从而有助于降低后期转移的风险。</p>
<p>“你可以像对待其他类型癌症一样，早期诊断和早期治疗，” Daniels 说，描述了如果 bel-sar 能够控制肿瘤并保护视力，治疗实践的预期转变。</p>
<p>Daniels 将 bel-sar 的视力保护特性与放疗进行了对比，表示接受放疗的患者中有 87% 的视力下降到低于 20/200，达到法律失明的阈值。他表示，接受放疗的患者平均视力损失约 30 个字母，而在 Aura 的 2 期研究中，平均接受 bel-sar 治疗的患者仅损失了三个字母。</p>
<h2>CoMpass 3 期试验设计</h2>
<p>Daniels 将 CoMpass 3 期研究描述为一项随机、盲法试验，比较三轮 80 微克 bel-sar 与假治疗。他表示，该方案与 CoMpass 所基于的 2 期方案相匹配。</p>
<p>参与 CoMpass 的患者必须有活跃生长的肿瘤，并在进入研究前有生长的记录。Daniels 表示，这一特征旨在确保随机到假治疗的患者可能会继续进展。</p>
<p>主要终点是肿瘤进展时间。第一个关键次要终点是肿瘤进展或视力丧失的复合体，以先发生者为准。Daniels 表示，欧洲和美国的监管机构一致认为肿瘤进展是主要终点，而复合次要终点可以支持关于视力保护的声明。</p>
<p>在讨论 2 期结果时，Daniels 表示接受治疗方案的患者有 80% 的肿瘤控制率，而低剂量的 “假治疗” 组中有 20% 的患者未达到进展阈值。他表示，停止 upfront bel-sar 治疗后，肿瘤控制在一年内得以维持。</p>
<h2>眼科肿瘤学的市场机会</h2>
<p>Daniels 表示，目前的编码实践可能低估了可能成为治疗候选者的患者数量，因为医生通常在决定用放疗治疗之前不会将病变编码为黑色素瘤。他表示，许多可能需要治疗的患者因担心放射相关的视力丧失而被监测更长时间。</p>
<p>当被问及潜在的治疗人群时，Daniels 表示，医生希望治疗的患者年发生率约为 8000 例，分布在美国和欧洲之间。</p>
<p>Gibney 表示，在停止疾病进展的同时保护视力可能在孤儿病中代表了一个重要的价值主张，特别是因为进入研究的患者通常在 50 多岁到 60 多岁之间。</p>
<h2>向其他眼癌的扩展</h2>
<p>Aura 还在追求 bel-sar 在脉络膜转移和眼表癌中的应用。Daniels 表示，脉络膜转移通常涉及乳腺癌和肺癌，以及其他肿瘤类型的小比例。这些病变可能快速生长，在视网膜下泄漏液体并导致视力丧失。</p>
<p>Daniels 表示，脉络膜转移的给药方法与脉络膜黑色素瘤相同，涉及超脉络膜注射和激光激活。他表示，这一设置可能使 Aura 能够在多种原发肿瘤类型中展示活性，因为肿瘤生长迅速，终点较短。</p>
<p>对于眼表癌，Daniels 表示适应症包括眼表面的黑色素瘤以及鳞状细胞癌和前驱病变。他将眼表疾病描述为 Aura 在会议上讨论的三个眼科肿瘤学机会中最大的一个。</p>
<p>Gibney 表示，最近的融资使 Aura 能够在结果良好的情况下更直接地将早期试点研究推进到后期开发。他补充说，治疗脉络膜黑色素瘤的医生通常也会治疗其他眼肿瘤，这意味着许多地点已经通过 CoMpass 熟悉了 bel-sar。</p>
<h2>膀胱癌项目和即将发布的数据</h2>
<p>Gibney 将膀胱癌领域描述为比眼科肿瘤学更大且更拥挤，尤其是在如原位癌和 BCG 不响应疾病等辅助治疗领域有显著活动。他表示，Aura 正在评估 bel-sar 是否可以提前转变治疗，包括在经尿道膀胱肿瘤切除术（TURBT）之前的新辅助方法。</p>
<p>他说 Aura 正在对患者进行 TURBT 前两周的治疗，并跟踪他们以观察 bel-sar 是否能在三个月和最终的十二个月内改善耐受性。Gibney 表示，公司还在探索一种免疫消融的方法，以便让可能避免 TURBT 的患者受益。</p>
<p>展望未来，Gibney 表示 Aura 预计将在年中发布三个月的膀胱癌数据，并预计在 2027 年下半年初发布十二个月的数据。他还表示，公司计划在 2026 年提供额外的核心数据和眼表疾病的初步概念验证工作。</p>
<h2>关于 Aura Biosciences NASDAQ: AURA</h2>
<p>Aura Biosciences 是一家临床阶段的生物制药公司，专注于开发新型病毒样颗粒（VLP）疗法用于癌症治疗。通过将专有的 VLP 技术与光激活染料相结合，Aura 旨在提供高度选择性的光动力疗法，针对并摧毁肿瘤细胞，同时保护健康组织。该公司的平台旨在解决眼科和非眼科环境中的实体肿瘤，利用近红外光的精确激活诱导局部肿瘤细胞凋亡并刺激抗肿瘤免疫反应。</p>
<p>主要产品候选药物 AU-011 正在对患有脉络膜黑色素瘤的患者进行评估，这是一种罕见但可能危及视力的眼癌。</p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aura Biosciences 吗？</h2>
<p>在考虑 Aura Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Aura Biosciences 并不在名单上。</p>
<p>虽然 Aura Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AURA

<p>Aura Biosciences（纳斯达克代码：AURA）高管在 H.C. Wainwright Connect 会议上介绍了他们针对 bel-sar 的战略，重点关注眼部肿瘤学和非肌肉侵袭性膀胱癌。该公司旨在解决脉络膜黑色素瘤的治疗挑战，强调 bel-sar 在控制肿瘤的同时保护视力的潜力。预计膀胱癌的 1b/2 期研究的初步数据将在年中公布。CoMpass 3 期试验将评估 bel-sar 与假治疗的疗效，主要终点为肿瘤进展时间</p>

<ul>
<li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备实现显著增长的小型股</li>
</ul>
</div><p>Aura Biosciences NASDAQ: AURA executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.</p>
<div class="lb-trans"><p>Aura Biosciences NASDAQ: AURA 的高管在 H.C. Wainwright Connect 会议上概述了公司针对其主要候选药物 bel-sar 的战略，强调眼科肿瘤学是公司初始的开发重点，同时讨论了在非肌肉侵袭性膀胱癌方面的持续工作。</p>
</div><p>Get <strong>Aura Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aura Biosciences</strong> 的提醒：</p>
</div><p>Tony Gibney, Aura’s Chief Financial Officer and Chief Business Officer, said the company’s pipeline is “founded on bel-sar,” which he described as a novel compound with potential utility across a broad range of solid tumors. Aura has chosen ocular oncology as its “beachhead” for proprietary development, beginning with choroidal melanoma and extending into metastases to the choroid and ocular surface cancers.</p>
<div class="lb-trans"><p>Aura 的首席财务官兼首席商务官 Tony Gibney 表示，公司管线 “以 bel-sar 为基础”，他将其描述为一种在广泛的实体肿瘤中具有潜在应用的新型化合物。Aura 选择眼科肿瘤学作为其专有开发的 “立足点”，从脉络膜黑色素瘤开始，并扩展到脉络膜转移和眼表癌。</p>
</div><p>Gibney also highlighted an ongoing Phase 1b/2 study in non-muscle invasive bladder cancer, with initial three-month data expected around mid-year. He said that program is evaluating both an immune-ablative opportunity and a neoadjuvant approach.</p>
<div class="lb-trans"><p>Gibney 还强调了在非肌肉侵袭性膀胱癌中进行的 1b/2 期研究，预计初步三个月的数据将在年中左右公布。他表示，该项目正在评估免疫消融机会和新辅助治疗方法。</p>
</div><h2>Bel-sar’s Role in Choroidal Melanoma</h2>
<div class="lb-trans"><h2>bel-sar 在脉络膜黑色素瘤中的作用</h2>
</div><p>Anthony Daniels, Vice President and Therapeutic Area Head of Ocular Oncology at Aura, said bel-sar is being developed to address a treatment dilemma in early choroidal melanoma: physicians often monitor growing tumors to delay radiotherapy because current radiation-based treatment can lead to severe vision loss.</p>
<div class="lb-trans"><p>Aura 眼科肿瘤学副总裁兼治疗领域负责人 Anthony Daniels 表示，bel-sar 的开发旨在解决早期脉络膜黑色素瘤的治疗困境：医生通常监测肿瘤的生长以延迟放疗，因为目前的放射治疗可能导致严重的视力丧失。</p>
</div><p>Daniels said patients with melanomas at the back of the eye ultimately face the risk of metastatic disease, most commonly involving spread to the liver. He said the current paradigm may treat too late, adding that bel-sar’s targeted tumor treatment may generate tumor-specific immune memory that could potentially help reduce the risk of later metastases.</p>
<div class="lb-trans"><p>Daniels 表示，眼后部的黑色素瘤患者最终面临转移性疾病的风险，最常见的是肝脏转移。他表示，目前的治疗模式可能治疗得太晚，并补充说，bel-sar 的靶向肿瘤治疗可能产生肿瘤特异性免疫记忆，从而有助于降低后期转移的风险。</p>
</div><p>“You can do what you do in every other type of cancer, which is diagnose early and treat early,” Daniels said, describing the intended shift in treatment practice if bel-sar can control tumors while preserving vision.</p>
<div class="lb-trans"><p>“你可以像对待其他类型癌症一样，早期诊断和早期治疗，” Daniels 说，描述了如果 bel-sar 能够控制肿瘤并保护视力，治疗实践的预期转变。</p>
</div><p>Daniels contrasted bel-sar’s vision preservation profile with radiotherapy, saying that with radiation, 87% of patients lose enough vision to fall below 20/200, the threshold for legal blindness. He said the average patient receiving radiation loses about 30 letters of vision, while in Aura’s Phase 2 study the average bel-sar-treated patient lost three letters.</p>
<div class="lb-trans"><p>Daniels 将 bel-sar 的视力保护特性与放疗进行了对比，表示接受放疗的患者中有 87% 的视力下降到低于 20/200，达到法律失明的阈值。他表示，接受放疗的患者平均视力损失约 30 个字母，而在 Aura 的 2 期研究中，平均接受 bel-sar 治疗的患者仅损失了三个字母。</p>
</div><h2>CoMpass Phase 3 Trial Design</h2>
<div class="lb-trans"><h2>CoMpass 3 期试验设计</h2>
</div><p>Daniels described the CoMpass Phase 3 study as a randomized, masked trial comparing three cycles of 80 micrograms of bel-sar with sham treatment. He said the regimen matches the Phase 2 regimen on which CoMpass was built.</p>
<div class="lb-trans"><p>Daniels 将 CoMpass 3 期研究描述为一项随机、盲法试验，比较三轮 80 微克 bel-sar 与假治疗。他表示，该方案与 CoMpass 所基于的 2 期方案相匹配。</p>
</div><p>Patients enrolled in CoMpass must have tumors that are actively growing with documentation of growth before entering the study. Daniels said that feature is intended to ensure patients randomized to sham are likely to continue progressing.</p>
<div class="lb-trans"><p>参与 CoMpass 的患者必须有活跃生长的肿瘤，并在进入研究前有生长的记录。Daniels 表示，这一特征旨在确保随机到假治疗的患者可能会继续进展。</p>
</div><p>The primary endpoint is time to tumor progression. The first key secondary endpoint is a composite of tumor progression or vision loss, whichever comes first. Daniels said regulators in both Europe and the U.S. aligned on tumor progression as the primary endpoint, and that the composite secondary endpoint could support claims around vision preservation.</p>
<div class="lb-trans"><p>主要终点是肿瘤进展时间。第一个关键次要终点是肿瘤进展或视力丧失的复合体，以先发生者为准。Daniels 表示，欧洲和美国的监管机构一致认为肿瘤进展是主要终点，而复合次要终点可以支持关于视力保护的声明。</p>
</div><p>In discussing Phase 2 results, Daniels said patients who received the therapeutic regimen had 80% tumor control, while a lower-dose “sham-like” group had 20% of patients who did not reach the progression threshold. He said tumor control was maintained for one year after upfront bel-sar treatment was stopped.</p>
<div class="lb-trans"><p>在讨论 2 期结果时，Daniels 表示接受治疗方案的患者有 80% 的肿瘤控制率，而低剂量的 “假治疗” 组中有 20% 的患者未达到进展阈值。他表示，停止 upfront bel-sar 治疗后，肿瘤控制在一年内得以维持。</p>
</div><h2>Market Opportunity in Ocular Oncology</h2>
<div class="lb-trans"><h2>眼科肿瘤学的市场机会</h2>
</div><p>Daniels said current coding practices may understate the number of patients who could be candidates for treatment because physicians generally do not code a lesion as melanoma until they decide to treat with radiation. He said many patients who may need treatment are monitored longer because of concerns about radiation-related vision loss.</p>
<div class="lb-trans"><p>Daniels 表示，目前的编码实践可能低估了可能成为治疗候选者的患者数量，因为医生通常在决定用放疗治疗之前不会将病变编码为黑色素瘤。他表示，许多可能需要治疗的患者因担心放射相关的视力丧失而被监测更长时间。</p>
</div><p>When asked about the potential treated population, Daniels said the incidence of patients doctors would want to treat is about 8,000 annually, split evenly between the U.S. and Europe.</p>
<div class="lb-trans"><p>当被问及潜在的治疗人群时，Daniels 表示，医生希望治疗的患者年发生率约为 8000 例，分布在美国和欧洲之间。</p>
</div><p>Gibney said preserving vision while halting disease progression could represent a significant value proposition in an orphan disease, particularly because patients entering the study are generally in their late 50s to early 60s.</p>
<div class="lb-trans"><p>Gibney 表示，在停止疾病进展的同时保护视力可能在孤儿病中代表了一个重要的价值主张，特别是因为进入研究的患者通常在 50 多岁到 60 多岁之间。</p>
</div><h2>Expansion Into Other Eye Cancers</h2>
<div class="lb-trans"><h2>向其他眼癌的扩展</h2>
</div><p>Aura is also pursuing bel-sar in metastases to the choroid and ocular surface cancers. Daniels said metastases to the choroid often involve breast and lung cancers, along with smaller percentages of other tumor types. These lesions can grow quickly, leak fluid under the retina and cause vision loss.</p>
<div class="lb-trans"><p>Aura 还在追求 bel-sar 在脉络膜转移和眼表癌中的应用。Daniels 表示，脉络膜转移通常涉及乳腺癌和肺癌，以及其他肿瘤类型的小比例。这些病变可能快速生长，在视网膜下泄漏液体并导致视力丧失。</p>
</div><p>Daniels said the delivery approach for metastases to the choroid is the same as in choroidal melanoma, involving suprachoroidal injection and laser activation. He said the setting could allow Aura to demonstrate activity across multiple primary tumor types, with shorter endpoints because the tumors grow quickly.</p>
<div class="lb-trans"><p>Daniels 表示，脉络膜转移的给药方法与脉络膜黑色素瘤相同，涉及超脉络膜注射和激光激活。他表示，这一设置可能使 Aura 能够在多种原发肿瘤类型中展示活性，因为肿瘤生长迅速，终点较短。</p>
</div><p>For ocular surface cancers, Daniels said the indication includes melanomas on the eye surface as well as squamous cell carcinoma and precursor lesions. He described ocular surface disease as the largest of Aura’s three ocular oncology opportunities discussed during the session.</p>
<div class="lb-trans"><p>对于眼表癌，Daniels 表示适应症包括眼表面的黑色素瘤以及鳞状细胞癌和前驱病变。他将眼表疾病描述为 Aura 在会议上讨论的三个眼科肿瘤学机会中最大的一个。</p>
</div><p>Gibney said a recent capital raise gives Aura the ability to move early pilot studies more directly into later development if results are favorable. He added that the same doctors who treat choroidal melanoma often treat the other ocular tumors, meaning many sites are already familiar with bel-sar through CoMpass.</p>
<div class="lb-trans"><p>Gibney 表示，最近的融资使 Aura 能够在结果良好的情况下更直接地将早期试点研究推进到后期开发。他补充说，治疗脉络膜黑色素瘤的医生通常也会治疗其他眼肿瘤，这意味着许多地点已经通过 CoMpass 熟悉了 bel-sar。</p>
</div><h2>Bladder Cancer Program and Upcoming Data</h2>
<div class="lb-trans"><h2>膀胱癌项目和即将发布的数据</h2>
</div><p>Gibney described the bladder cancer field as larger and more crowded than ocular oncology, with significant activity in adjuvant treatment settings such as carcinoma in situ and BCG-unresponsive disease. He said Aura is evaluating whether bel-sar can shift treatment earlier, including a neoadjuvant approach before transurethral resection of bladder tumor, or TURBT.</p>
<div class="lb-trans"><p>Gibney 将膀胱癌领域描述为比眼科肿瘤学更大且更拥挤，尤其是在如原位癌和 BCG 不响应疾病等辅助治疗领域有显著活动。他表示，Aura 正在评估 bel-sar 是否可以提前转变治疗，包括在经尿道膀胱肿瘤切除术（TURBT）之前的新辅助方法。</p>
</div><p>He said Aura is treating patients two weeks before TURBT and following them to see whether bel-sar can improve durability at three months and ultimately 12 months. Gibney said the company is also exploring an immune-ablative approach in patients who may be able to avoid TURBT.</p>
<div class="lb-trans"><p>他说 Aura 正在对患者进行 TURBT 前两周的治疗，并跟踪他们以观察 bel-sar 是否能在三个月和最终的十二个月内改善耐受性。Gibney 表示，公司还在探索一种免疫消融的方法，以便让可能避免 TURBT 的患者受益。</p>
</div><p>Looking ahead, Gibney said Aura expects three-month bladder cancer data around mid-year, with 12-month data projected for the early second half of 2027 based on that timing. He also said the company is guiding to additional core data and initial proof-of-concept work in ocular surface disease in 2026.</p>
<div class="lb-trans"><p>展望未来，Gibney 表示 Aura 预计将在年中发布三个月的膀胱癌数据，并预计在 2027 年下半年初发布十二个月的数据。他还表示，公司计划在 2026 年提供额外的核心数据和眼表疾病的初步概念验证工作。</p>
</div><h2>About Aura Biosciences NASDAQ: AURA</h2>
<div class="lb-trans"><h2>关于 Aura Biosciences NASDAQ: AURA</h2>
</div><p>Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.</p>
<div class="lb-trans"><p>Aura Biosciences 是一家临床阶段的生物制药公司，专注于开发新型病毒样颗粒（VLP）疗法用于癌症治疗。通过将专有的 VLP 技术与光激活染料相结合，Aura 旨在提供高度选择性的光动力疗法，针对并摧毁肿瘤细胞，同时保护健康组织。该公司的平台旨在解决眼科和非眼科环境中的实体肿瘤，利用近红外光的精确激活诱导局部肿瘤细胞凋亡并刺激抗肿瘤免疫反应。</p>
</div><p>The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.</p>
<div class="lb-trans"><p>主要产品候选药物 AU-011 正在对患有脉络膜黑色素瘤的患者进行评估，这是一种罕见但可能危及视力的眼癌。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aura Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aura Biosciences 吗？</h2>
</div><p>Before you consider Aura Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aura Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Aura Biosciences 并不在名单上。</p>
</div><p>While Aura Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aura Biosciences 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aura Biosciences 强调 Bel-Sar 眼癌策略及年中膀胱数据